Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AVDL Avadel Pharmaceuticals Plc
- Stocks
- Healthcare
- NASDAQ: AVDL
Price (delayed)
$9.39
Market cap
$908.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.27
Enterprise value
$890.42M
Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime
Highlights
Avadel Pharmaceuticals's EPS has surged by 85% YoY and by 47% QoQ
Avadel Pharmaceuticals's net income has soared by 83% YoY and by 46% from the previous quarter
AVDL's quick ratio is down by 9% year-on-year and by 4.1% since the previous quarter
The company's equity fell by 6% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.avadel.com
Key stats
What are the main financial stats of AVDL
Market
Valuations
Earnings
Shares outstanding
96.74M
Market cap
$908.38M
Enterprise value
$890.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
12.25
Price to sales (P/S)
4.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.58
Revenue
$194.45M
Gross profit
$175.12M
Operating income
-$19.37M
Net income
-$26.41M
EBIT
-$16.2M
EBITDA
-$13.23M
Free cash flow
-$25.44M
Per share
Balance sheet
Liquidity
EPS
-$0.27
EPS diluted
-$0.27
Free cash flow per share
-$0.26
Book value per share
$0.77
Revenue per share
$2.01
TBVPS
$1.56
Total assets
$167.95M
Total liabilities
$93.88M
Debt
$38.41M
Equity
$74.07M
Working capital
$88.33M
Debt to equity
0.52
Current ratio
2.73
Quick ratio
2.12
Net debt/EBITDA
1.36
Margins
Efficiency
Dividend
EBITDA margin
-6.8%
Gross margin
90.1%
Net margin
-13.6%
Operating margin
-10%
Return on assets
-16.3%
Return on equity
-36.1%
Return on invested capital
-17.2%
Return on capital employed
-13.8%
Return on sales
-8.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVDL stock price
How has the Avadel Pharmaceuticals stock price performed over time
Intraday
0%
1 week
7.99%
1 month
29.34%
1 year
-40.68%
YTD
-10.66%
QTD
19.92%
Financial performance
How have Avadel Pharmaceuticals's revenue and profit performed over time
Revenue
$194.45M
Gross profit
$175.12M
Operating income
-$19.37M
Net income
-$26.41M
Gross margin
90.1%
Net margin
-13.6%
AVDL's operating margin has soared by 96% YoY and by 60% QoQ
The net margin has surged by 95% year-on-year and by 53% since the previous quarter
The company's operating income has surged by 86% YoY and by 54% QoQ
Avadel Pharmaceuticals's net income has soared by 83% YoY and by 46% from the previous quarter
Price vs fundamentals
How does AVDL's price correlate with its fundamentals
Growth
What is Avadel Pharmaceuticals's growth rate over time
Valuation
What is Avadel Pharmaceuticals stock price valuation
P/E
N/A
P/B
12.25
P/S
4.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.58
Avadel Pharmaceuticals's EPS has surged by 85% YoY and by 47% QoQ
The stock's price to book (P/B) is 36% more than its 5-year quarterly average of 9.0 but 18% less than its last 4 quarters average of 15.0
The company's equity fell by 6% YoY
The price to sales (P/S) is 44% lower than the last 4 quarters average of 8.3
The revenue has grown by 15% from the previous quarter
Efficiency
How efficient is Avadel Pharmaceuticals business performance
Avadel Pharmaceuticals's return on sales has surged by 97% YoY and by 63% QoQ
The ROIC has soared by 87% YoY and by 55% from the previous quarter
AVDL's return on assets has surged by 81% year-on-year and by 46% since the previous quarter
The ROE has soared by 76% YoY and by 45% from the previous quarter
Dividends
What is AVDL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVDL.
Financial health
How did Avadel Pharmaceuticals financials performed over time
The total assets is 79% more than the total liabilities
AVDL's quick ratio is down by 9% year-on-year and by 4.1% since the previous quarter
AVDL's total liabilities is up by 4.9% YoY and by 3.9% QoQ
The debt is 48% smaller than the equity
Avadel Pharmaceuticals's debt to equity has increased by 11% YoY and by 4% from the previous quarter
The company's equity fell by 6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.